{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:49:50Z","timestamp":1788112190740,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1053\/j.ajkd.2024.01.527","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T17:14:51Z","timestamp":1710263691000},"page":"224-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review"],"prefix":"10.1053","volume":"84","author":[{"given":"Evelyn","family":"Mel\u00e9ndrez-Balc\u00e1zar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Aranda-Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cervantes-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"L\u00f3pez-Cure\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ajkd.2024.01.527_bib1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/CND.0000000000000270","article-title":"Hereditary transthyretin amyloidosis: clinical presentation and management updates: clinical presentation and management updates","volume":"21","author":"Schwartzlow","year":"2020","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2024.01.527_bib2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033969","article-title":"Modulation of amyloid states by molecular chaperones","volume":"11","author":"Wentink","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1053\/j.ajkd.2024.01.527_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijbiomac.2013.05.032","article-title":"Applying chaperones to protein-misfolding disorders: Molecular chaperones against \u03b1-synuclein in Parkinson\u2019s disease","volume":"60","author":"Chaari","year":"2013","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.527_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol Ther"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.527_bib5","first-page":"2109","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.527_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccl.2021.04.010","article-title":"Advances in diagnosis and treatment of cardiac and renal amyloidosis","volume":"39","author":"Law","year":"2021","journal-title":"Cardiol Clin"},{"issue":"101388","key":"10.1053\/j.ajkd.2024.01.527_bib7","article-title":"Age-related amyloidosis outside the brain: A state-of-the-art review","volume":"70","author":"Tasaki","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.527_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/gerona\/59.4.M361","article-title":"Amyloidosis: a universal disease of ageing?","volume":"59","author":"Blumenthal","year":"2004","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"10.1053\/j.ajkd.2024.01.527_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1053\/j.ajkd.2022.08.018","article-title":"Focal segmental glomerulosclerosis complicating therapy with inotersen, an antisense oligonucleotide inhibitor: a case report","volume":"81","author":"Law","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"21","key":"10.1053\/j.ajkd.2024.01.527_bib10","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13023-021-01910-5","article-title":"Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden","volume":"16","author":"Gonz\u00e1lez-Moreno","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-2836(74)90291-5","article-title":"Structure of human plasma prealbumin at 2.5 A resolution","volume":"88","author":"Blake","year":"1974","journal-title":"J\u00a0Mol Biol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.527_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0006-291X(85)80027-9","article-title":"High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain","volume":"127","author":"Dickson","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"issue":"21","key":"10.1053\/j.ajkd.2024.01.527_bib14","doi-asserted-by":"crossref","first-page":"11793","DOI":"10.1016\/S0021-9258(17)39100-7","article-title":"Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat","volume":"260","author":"Soprano","year":"1985","journal-title":"J\u00a0Biol Chem"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.527_bib15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/archneur.56.9.1152","article-title":"Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64","volume":"56","author":"Uemichi","year":"1999","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update onpahophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib17","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140155","article-title":"Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage","volume":"35","author":"Manral","year":"2015","journal-title":"Biosci Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2024.01.527_bib18","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.527_bib19","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1073\/pnas.0400062101","article-title":"Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture","volume":"101","author":"Reixach","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15424-3","article-title":"Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells","volume":"7","author":"Imperlini","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"10.1053\/j.ajkd.2024.01.527_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","article-title":"The proteostasis network and its decline in ageing","volume":"20","author":"Hipp","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"10.1053\/j.ajkd.2024.01.527_bib22","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.527_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13506129.2011.565524","article-title":"Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis","volume":"18","author":"Koike","year":"2011","journal-title":"Amyloid"},{"key":"10.1053\/j.ajkd.2024.01.527_bib25","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x2022e12284","article-title":"Renal amyloidosis: a new time for a complete diagnosis","volume":"55","author":"Feitosa","year":"2022","journal-title":"Braz J Med Biol Res"},{"issue":"12","key":"10.1053\/j.ajkd.2024.01.527_bib26","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease","volume":"17","author":"Dember","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.527_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s10157-016-1271-y","article-title":"Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience","volume":"21","author":"Ozawa","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.527_bib28","first-page":"343","article-title":"Pathology and diagnosis of renal non-AL amyloidosis","volume":"31","author":"Sethi","year":"2018","journal-title":"J\u00a0Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2024.01.527_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13506129.2003.12088560","article-title":"The pathogenesis of transthyretin tissue deposition: lessons from transgenic mice","volume":"10","author":"Buxbaum","year":"2003","journal-title":"Amyloid"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.527_bib30","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0002-9440(10)63050-7","article-title":"Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates","volume":"159","author":"Sousa","year":"2001","journal-title":"Am J Pathol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2024.01.527_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/13506129.2003.12088568","article-title":"Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations","volume":"10","author":"Westermark","year":"2003","journal-title":"Amyloid"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.527_bib32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/ajkd.1998.v31.pm9631837","article-title":"Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits","volume":"31","author":"Lobato","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2024.01.527_bib33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/brain\/122.10.1951","article-title":"Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan: clinicopathological and genetic features","volume":"122","author":"Misu","year":"1999","journal-title":"Brain"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.527_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13506120600722662","article-title":"Value of renal biopsy in the prognosis of liver transplantation in familial amyloid polyneuropathy ATTR Val30Met patients","volume":"13","author":"Oguchi","year":"2006","journal-title":"Amyloid"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.527_bib35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1440-1827.1997.tb04508.x","article-title":"Late onset type I familial amyloidotic polyneuropathy: presentation of three autopsy cases in comparison with 19 autopsy cases of the ordinary type","volume":"47","author":"Takahashi","year":"1997","journal-title":"Pathol Int"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.527_bib36","first-page":"309","article-title":"Postmortem findings in primary familial amyloidosis with polyneuropathy: a study based on six cases from northern Sweden","volume":"83A","author":"Hofer","year":"2009","journal-title":"Acta Pathol Microbiol Scand A"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.527_bib37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","article-title":"Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy","volume":"18","author":"Lobato","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.527_bib38","first-page":"438","article-title":"Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M)","volume":"16","author":"Lobato","year":"2003","journal-title":"J\u00a0Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.527_bib39","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","article-title":"Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients","volume":"15","author":"Solignac","year":"2022","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1053\/j.ajkd.2024.01.527_bib40","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3390\/brainsci11080980","article-title":"Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience","volume":"11","author":"Ferraro","year":"2021","journal-title":"Brain Sci"},{"key":"10.1053\/j.ajkd.2024.01.527_bib41","series-title":"A\u00a0nefropatia na polineuropatia amiloid\u00f3tica familiar de tipo Portugu\u00eas. PhD diss","author":"Lobato","year":"2012"},{"key":"10.1053\/j.ajkd.2024.01.527_bib42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","article-title":"Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis","author":"Carroll","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.ajkd.2024.01.527_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care","volume":"16","author":"Luigetti","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"10.1053\/j.ajkd.2024.01.527_bib44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.527_bib47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges: liver transplantation in ATTR","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.527_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"issue":"12","key":"10.1053\/j.ajkd.2024.01.527_bib49","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3390\/genes13122236","article-title":"Trajectories of kidney function in patients with ATTRv treated with gene silencers","volume":"13","author":"Luigetti","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1053\/j.ajkd.2024.01.527_bib50","article-title":"Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation","author":"Badri","year":"2024","journal-title":"Journal of the American Medical Association"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.527_bib51","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/ehf2.13443","article-title":"Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature","volume":"8","author":"Adam","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"sup1","key":"10.1053\/j.ajkd.2024.01.527_bib52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/13506129.2016.1277697","article-title":"Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule","volume":"24","author":"Rocha","year":"2017","journal-title":"Amyloid"},{"issue":"8853","key":"10.1053\/j.ajkd.2024.01.527_bib53","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis","volume":"341","author":"Holmgren","year":"1993","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","article-title":"Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients","volume":"7","author":"Yazaki","year":"2007","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1432-2277.2004.00015.x","article-title":"The long-term impact of liver transplantation on kidney function in familial amyloidotic polyneuropathy patients","volume":"18","author":"Nowak","year":"2005","journal-title":"Transpl Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.transproceed.2010.11.014","article-title":"Characterization of end-stage renal disease after liver transplantation in transthyretin amyloidosis (ATTR V30M)","volume":"43","author":"Rocha","year":"2011","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.527_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trre.2016.09.002","article-title":"Liver transplantation in transthyretin amyloidosis: characteristics and management related to kidney disease","volume":"31","author":"Rocha","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4254\/wjh.v14.i1.45","article-title":"Current aspects of renal dysfunction after liver transplantation","volume":"14","author":"Pacheco","year":"2022","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.527_bib59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","article-title":"The many faces of calcineurin inhibitor toxicity\u2014what the FK?","volume":"27","author":"Farouk","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2024.01.527_bib60","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/ndt\/gfh063","article-title":"Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation","volume":"19","author":"Snanoudj","year":"2004","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624006760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624006760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:29:08Z","timestamp":1721384948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624006760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0272638624006760"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.01.527","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.01.527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}